Dean Elterman

About

Dean Elterman is a urologist whose research has become synonymous with advancing minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), with a particular focus on Aquablation therapy. His work has meaningfully shaped how urologists approach large-volume prostates — a historically challenging clinical problem — by rigorously evaluating the safety, efficacy, and durability of robotic waterjet ablation as an alternative to open surgery. Elterman's most impactful contributions include leading the WATER II clinical trial, which followed 101 men with large prostates (80–150 cc) over five years, demonstrating sustained outcomes and establishing long-term evidence for Aquablation in complex cases. His 2019 one-year results paper alone has garnered 63 citations, while his broader reviews of ablative therapies including Rezūm and transperineal laser ablation have become key reference points for trainees and practicing urologists alike. He has also advanced practical questions around hemostasis techniques, early adoption learning curves, outcomes in elderly patients, and patient decision-making tools, reflecting a comprehensive, patient-centered research philosophy. With nearly 350 combined citations across his top works, Elterman stands as a leading voice in evidence-based BPH surgical innovation.

Research Focus

Key Achievements

Top Papers

1. 1
   Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results

   63 citations · 2019
2. 2
   Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation

   58 citations · 2023
3. 3
   Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results

   49 citations · 2023
4. 4
   Transfusion rates after 800 Aquablation procedures using various haemostasis methods

   45 citations · 2020
5. 5
   WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates

   25 citations · 2021
6. 6
   Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results.

   24 citations · 2020
7. 7
   Aquablation among novice users in Canada: A WATER II subpopulation analysis

   17 citations · 2018
8. 8
   Evaluating the acceptability of an online patient decision aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia

   17 citations · 2021
9. 9
   Accuracy of Clarius, Handheld Wireless Point-of-Care Ultrasound, in Evaluating Prostate Morphology and Volume Compared to Radical Prostatectomy Specimen Weight: Is There a Difference between Transabdominal <i>vs</i> Transrectal Approach?

   17 citations · 2021
10. 10
    Functional and surgical outcomes of Aquablation in elderly men

    16 citations · 2022

Key Collaborators

Contact & Links